^
Association details:
| Biomarker: | CTLA4 promoter hypomethylation |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma
Published date:
07/06/2023
Excerpt:
We analyzed CTLA4 promoter methylation in tumors of HNSCC patients (N = 29) treated with ICB...Lower CTLA4 promoter methylation correlated with response to ICB and prolonged progression-free survival….Our results indicate that CTLA4 DNA hypomethylation is a predictive biomarker for response to ICB in HNSCC.
DOI:
10.1186/s13148-023-01525-6
